3 numbers that explain Bristol Myers Squibb's dirt cheap valuation

MSN

Sep 29, 2026 at 10:41 AM

With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and looming patent cliff.

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

3 numbers that explain Bristol Myers Squibb's dirt cheap valuation

Recommended Readings